Direct Oral Anticoagulants versus Warfarin in Atrial Fibrillation An Economic Perspective

Abstract

Background: Atrial fibrillation is a kind of supraventricular arrhythmia that impairs heart function and raises the risk of stroke. It is the most frequent arrhythmia and a significant cause of morbidity and mortality; its frequency rises with age. Aim. To compare the benefits versus risks of vitamin K dependent anticoagulant (warfarin) versus direct acting anticoagulants and antiplatelet therapy.Method: Literature resources were searched to compare benefits and risks of different anticoagulants used in atrial fibrillation. Results and Discussion:The CHADs-2-Vasc score predicts the likelihood of Stroke. Based on the assessment score, anticoagulant medication is advised. Stroke preventive medications include warfarin, dabigatran, rivaroxaban, and aspirin. Conclusion:Rivaroxaban, and dabigatran showed superior effect and less risks of stroke incidence over warfarin in atrial fibrillation patients. Furthermore, individualized therapy selection should be based on risks and possible benefits, expense, and patient desire.